IRLAB Therapeutics investor relations material

Listen to the latest call from IRLAB Therapeutics

IRLAB Therapeutics AB is a research and development company developing drugs for the treatment of Parkinson's disease. IRLAB develops drugs that can stop or slow down the loss of neurons in the substantia nigra, where dopamine is produced. In Parkinson's disease, loss of these neurons leads to a gradual degeneration of the motor functions. These drugs will improve symptoms without dramatically increasing the risk of side effects.

  • Ticker

  • Country


Dig deeper into the IRLAB Therapeutics fundamentals on Quartr.